Challenge Company D, a privately-held clinical stage biotechnology company engaged in a merger agreement with a publicly traded clinical stage pharmaceutical company and engaged CFGI to assist with audit preparation, accounting and reporting obligations in connection with the merger.
Challenge Company B, a $100MM foreign medical diagnostic company initiated IPO on domestic Form S-1, converting accounting basis from UK GAAP to US GAAP and reporting currency from Pounds Sterling to the US Dollar.
Challenge Company A, a biotech with a Phase II clinical trial asset, engaged CFGI to provide assistance with audit preparation and preparation of Form S-1 in connection with their initial public offering.
Challenge Company C, a US-based clinical research organization, completed an acquisition of a significant business based in Europe.
